Skip to main content
OpenTrials
Completed

NCT Number: NCT03805412

Continuous Glucose Monitoring in Diabetes and Prediabetes

Evaluate the use of brief serial real time continuous monitoring (RT-CGM) as a behavior modification tool in obese patients with prediabetes and diabetes. After receiving RT-CGM, nutrition and exercise education, participants will be able to monitor their blood sugar in real time for 2 sessions . Education on how to interpret CGM in the setting of food choices and exercise coupled with nutrition and exercise information should lead to improved weight and other nutritional and exercise changes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Mellitus, Type 2 Body Weight Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms PreDiabetes Prediabetic State Signs and Symptoms

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

GWU Medical Faculty Associates

Washington D.C., District of Columbia, 20037, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-55
  • Prediabetes (A1c 6.0-6.4) or Diabetes (A1c 7.0-10)
  • BMI ≥ 30 kg/m2
  • Willing to wear pedometer during study period
  • Able to walk 2 city blocks at baseline without assistance (self-reported)
  • Reading level at least 6th grade in English
  • Expected to remain in local community for at least 4 months
  • Either is not treated with or has been on a stable treatment regimen of any of the following medications for a minimum of 3 months prior to Visit 1 (Screening/Enrollment):
  • Sulfonylureas
  • Biguanidine
  • Thyroid replacement therapy
  • Glp-1 agonists
  • Sodium-glucose co-transporters
  • Basal insulin
  • Thiazolidinediones
  • Hormone replacement therapy (female subjects) estrogen/progesterone products
  • Oral contraceptives/birth control (female subjects)
  • Antidepressant agents (SSRIs, Paxil, Prozac, Celexa, Zoloft, etc.)
  • Is able to read, understand, and sign the Informed Consent Form (ICF) and if applicable, an Authorization to Use and Disclose Protected Health Information form (consistent with Health Insurance Portability and Accountability Act of 1996 [HIPAA] legislation), communicate with the investigator, and understand and comply with protocol requirements.

Exclusion criteria

  • Women who are pregnant, lactating, planning to become pregnant
  • Subjects who are taking amphetamines, anabolic, or weight-reducing agents
  • Contraindications to moderate exercise
  • Pre-prandial insulin
  • On any antipsychotic medication or history of schizophrenia or bipolar disorder
  • Daily use of any form of steroid medication (oral, inhaled, injected) within the last 3 months
  • Active wounds or recent surgery within 3 months
  • Inflammatory disease, or chronic and current use of anti-inflammatory drugs or narcotics
  • Active cardiovascular diseases within 12 months of Visit 1, such as myocardial infarction, clinically significant arrhythmia, unstable angina, coronary artery bypass surgery, or angioplasty; or are expected to require coronary artery bypass surgery or angioplasty during the course of the study
  • Presence or history of severe congestive heart failure (New York Heart Association Class IV [CCNYHA 1994])
  • Has evidence of current abuse of drugs or alcohol or a history of abuse that, in the investigator's opinion, would cause the individual to be noncompliant
  • Enrolled in another weight loss program
  • Already receiving continuous glucose monitoring (CGM)

Treatment and study plan

DEXCOM G6 RT-CGM

Device

CGM is a way to measure glucose levels in real-time. A tiny electrode called a glucose sensor is inserted under the skin to measure glucose levels in tissue fluid. A small plastic piece of tube remains inserted in the skin. It is connected to a transmitter that sits on top of the skin. It is approved for use on the abdomen for 10 days. It either records the sugars downloaded in the clinic (blinded part of the study) or it sends the information via wireless radio frequency to a monitoring/ display device or to a cellular phone so participants can see data. DEXCOM G6 is FDA approved for use in patients with diabetes and will be used in accordance with instructions as approved for diabetes.

Primary outcomes

  1. Percent Change in BMI From Baseline to 14 Weeks

    Time frame: 14 weeks

    weight and height will be combined to report % change BMI in kg/m^2 at 14 weeks

  2. Percent Body Fat Change at 14 Weeks

    Time frame: 14 weeks

    Percent by Tanita scale

Secondary outcomes

  1. Questionnaire: Experiences With Glucose Monitoring (CGM) Diabetes

    Time frame: 14 weeks

    Experiences of CGM @Joslin 2009 scale of (5) strongly agree or (1) strongly disagree about statements/questions that measured the amount of satisfaction that was derived from continuous glucose monitoring. The larger the score the more satisfied participants were with CGM. 100 being the max score and 20 being the min score

  2. Mean Glucose Change at 14 Weeks

    Time frame: 14 weeks

    average glucose during 10 days of wearing continuous glucose monitoring (CGM) at baseline and 14 weeks

  3. Food Frequency Change in Score at 14 Weeks

    Time frame: 14 weeks

    Starting The Conversation (STC) is an eight-item simplified food frequency instrument/questionnaire a max score of 16 indicates poor food choices and a minimum score of 0 indicates good food choices. Results reported is change from baseline score with a negative score being a marker of improvement in food choices and a positive score being worsening of food choices

  4. Change in Minutes Walked Per Week at 14 Weeks

    Time frame: 14 weeks

    The International Physical Activity Questionnaire(short) is as validated questionnaire which asks the time in minutes or hours in last week you do vigorous exercise, moderate intensity exercise, walking and sitting

  5. MAGE Mean Amplitude of Glycemic Excursion

    Time frame: 14 weeks

    this is calculation of variance of glucose for CGM

Sponsors and collaborators

Lead sponsor

Nicole Ehrhardt, MD

Other

Collaborators

  • DexCom, Inc.

Registry information

Official study title

A Pilot Study on the Use of Real-Time Continuous Glucose Monitoring (RT-CGM) as an Educational Tool for Patients With Prediabetes and Diabetes

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Jan 15, 2019
Registry last updated
Mar 1, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.